Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Developments study located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,